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ABSTRACT Streptococcus pneumoniae is an important commensal and pathogen responsible for almost a million deaths annually
in children under five. The formation of biofilms by S. pneumoniae is important in nasopharyngeal colonization, pneumonia,
and otitis media. Pneumolysin (Ply) is a toxin that contributes significantly to the virulence of S. pneumoniae and is an impor-
tant candidate as a serotype-independent vaccine target. Having previously demonstrated that a luxS knockout mutant was un-
able to form early biofilms and expressed less plymRNA than the wild type, we conducted a study to investigate the role of Ply in
biofilm formation.We found that Ply was expressed in early phases of biofilm development and localized to cellular aggregates
as early as 4 h postinoculation. S. pneumoniae ply knockout mutants in D39 and TIGR4 backgrounds produced significantly less
biofilm biomass than wild-type strains at early time points, both on polystyrene and on human respiratory epithelial cells, cul-
tured under static or continuous-flow conditions. Ply’s role in biofilm formation appears to be independent of its hemolytic ac-
tivity, as S. pneumoniae serotype 1 strains, which produce a nonhemolytic variant of Ply, were still able to form biofilms. Trans-
mission electronmicroscopy of biofilms grown on A549 lung cells using immunogold demonstrated that Ply was located both on
the surfaces of pneumococcal cells and in the extracellular biofilmmatrix. Altogether, our studies demonstrate a novel role for
pneumolysin in the assembly of S. pneumoniae biofilms that is likely important during both carriage and disease and therefore
significant for pneumolysin-targeting vaccines under development.
IMPORTANCE The bacterium Streptococcus pneumoniae (commonly known as the pneumococcus) is commonly carried in the
human nasopharynx and can spread to other body sites to cause disease. In the nasopharynx, middle ear, and lungs, the pneu-
mococcus formsmulticellular surface-associated structures called biofilms. Pneumolysin is an important toxin produced by al-
most all S. pneumoniae strains, extensively studied for its ability to cause damage to human tissue. In this paper, we demonstrate
that pneumolysin has a previously unrecognized role in biofilm formation by showing that strains without pneumolysin are un-
able to form the same amount of biofilm on plastic and human cell substrates. Furthermore, we show that the role of pneumoly-
sin in biofilm formation is separate from the hemolytic activity responsible for tissue damage during pneumococcal diseases.
This novel role for pneumolysin suggests that pneumococcal vaccines directed against this protein should be investigated for
their potential impact on biofilms formed during carriage and disease.
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Streptococcus pneumoniae (the pneumococcus) is a Gram-positive bacterium annually responsible for 14.5 million cases
of disease and 800,000 deaths in children under 5 years of age (1).
The pneumococcus colonizes the nasopharynx in up to 90% of
children and approximately 15% of adults and can spread from
there to other anatomic sites to cause sinusitis, otitis media, pneu-
monia, bacteremia, and meningitis (2). Biofilm formation is im-
portant, both for colonization of the human nasopharynx and in
pathogenesis (3). In particular, the role of pneumococcal biofilms
in otitis media has been clearly demonstrated in humans (4) and
investigated in a chinchilla model (5, 6). Despite the relevance of
biofilms in commensalism and pathogenesis, the mechanisms of
pneumococcal biofilm formation are not yet fully understood.
Our laboratories have previously demonstrated that LuxS, the au-
toinducer 2 (AI-2) synthase, is essential for biofilm formation at
early time points (7, 8) and observed that transcription of ply, the
gene that encodes pneumolysin, is down-regulated approximately
35-fold in a luxS-null mutant (7).
Pneumolysin (Ply) is a well-established virulence factor (9, 10)
that has been extensively studied for its hemolytic activity and
cytotoxic properties. Ply, a 53-kDa surface protein (11), is a
cholesterol-dependent cytolysin that binds cholesterol in eukary-
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otic cell membranes and forms 400-Å pores that lead to cell lysis
(12). Through its activity at the bacterial cell surface, or upon
release through pneumococcal autolysis, Ply is responsible for al-
most all pneumococcal hemolytic activity (13). As anti-Ply anti-
bodies are generated following carriage or otitis media (14–16)
andTLR4-mediated recognition of pneumolysin stimulates a pro-
found immune response (17, 18), a detoxified derivative of pneu-
molysin is under investigation as a serotype-independent vaccine
candidate (19–21). However, it is currently unclear what role Ply
plays during asymptomatic carriage that exposes this protein to
the host immune system.
Though prior studies have demonstrated that the hemolytic
alpha-toxin of Staphylococcus aureus is essential for biofilm for-
mation on plastic and ex vivo porcine mucosa (22, 23), we are
unaware of any other hemolysins being directly implicated in bio-
film formation. That said, some preliminary data suggest that Ply
has a role in pneumococcal biofilm development. A study of
S. pneumoniae ATCC 6303 biofilms in a continuous-flow system
demonstrated more Ply present in 3-day-old biofilms than in
planktonic cultures (24), andmore recently, Marks et al. reported
that 48-h biofilms formed by a Ply-deficient mutant, grown on
NCI-H292 epithelial cells with medium replacement every 12
hours, differed in appearance and biomass from wild-type D39
(25). Furthermore, our previous study of the role of LuxS/AI-2 in
biofilm development suggests that genes regulated by LuxS, in-
cluding ply (7, 26), the putative hemolysin SP1466 (26), and the
cbpD gene, encoding choline-binding protein D (CbpD), may be
important in biofilm development. While it has been shown that
CbpD is required for biofilm formation (8), the role of pneumo-
lysin in biofilm development has not been thoroughly investi-
gated.
To assess whether Ply has a part in pneumococcal biofilm for-
mation, we examined the timing and distribution of Ply expres-
sion in pneumococcal biofilms and evaluated biofilm formation
of Ply knockout mutants under static and continuous-flow con-
ditions, on both abiotic and human cell substrates. We found that
Ply is expressed in pneumococcal biofilms, localizing to the earli-
est aggregates of cells, and knockout mutants deficient in Ply are
impaired in their ability to form biofilms. While biofilm forma-
tion appears tomask the hemolytic activity of pneumococcal cells,
pneumolysin’s role in biofilm formation appears to be separate
from its hemolytic activity. Altogether, our results demonstrate a
novel and important role for Ply in the early development of pneu-
mococcal biofilms.
RESULTS
Pneumolysin is expressed in pneumococcal biofilms. We first
examinedwhether Ply was expressed inwild-typeD39 during bio-
film development in static cultures on a polystyrene substrate. To
visualize Ply in biofilms, we employed a mouse monoclonal anti-
Ply antibody followed by a fluorescently labeled anti-mouse anti-
body. Immunofluorescence images revealed low levels of Ply ex-
pression in biofilms 4 h and 6 h postinoculation, followed by
maximal expression 8 h postinoculation and decreased expression
FIG 1 Pneumolysin is expressed in S. pneumoniae biofilms. (A) Fluorescence microscopy of wild-type D39 biofilms visualized with an anti-Ply antibody and a
secondary conjugated antibody demonstrates Ply expression at 4, 6, 8, and 18 h. (B) Cell lysates from wild-type D39 grown in planktonic cultures or biofilms
grown on polystyrene plates were probed byWestern blotting. (C) To examine pneumolysin expression over time qPCR of cDNAwas used to compare levels of
ply mRNA at different time points of biofilm formation on polystyrene. Levels of ply mRNA were compared between the inoculum (0 h) and the 6-h biofilm,
between 6-h and 12-h biofilms, and between 12-h and 24-h biofilms. (D) qPCR comparing levels of mRNA in 6-h biofilms to 12-h biofilms, showing that those
formed by wild-type D39 have significantly more plymRNA than those formed by D39luxS. Error bars indicate standard errors of the means, and the asterisk
indicates a P value of 0.01.
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by 18 h (Fig. 1A). As a control, we probed 18-h biofilms of a ply
knockout mutant (see Fig. S1 in the supplemental material) with
the anti-Ply antibody and observed minimal fluorescence (see
Fig. S2 in the supplementalmaterial).Western blotting confirmed
that pneumolysin is present in both planktonic and biofilm cells as
early as 2 h postinoculation and reaches maximal expression 6 to
8 h following inoculation (Fig. 1B). Using reverse transcriptase
and qPCR to quantify pneumolysin mRNA in biofilm cells, we
found that ply expression increased from 0 to 6 h and from 6 to
12 h but there was little change in mRNA levels between 12 and
24 h (Fig. 1C). In line with our previous finding that ply is down-
regulated in planktonic cultures of D39luxS (7), we found that
the change in ply expression between 6 and 12 h in biofilms
formedbyD39luxSwas significantly less than in biofilms formed
by wild-type D39 (Fig. 1D).
Pneumolysin localizes to cellular aggregates and is present in
the cellwall and extracellularmatrix.Using confocalmicroscopy
to examine the location of Ply in three dimensions using an anti-
Ply antibody and green fluorescent protein (GFP)-expressing
wild-type D39 biofilms, we found that Ply colocalized with aggre-
gates of biofilm cells (Fig. 2A). To confirm that the pneumolysin
signal was specific to aggregates and not simply coincidental with
the largest mass of cells, we examined sparse 4-h biofilms. Using
differential interference contrast (Nomarski) images overlaidwith
images obtained using an anti-Ply antibody and a fluorescently
labeled secondary antibody, we found that the Ply signal localized
to nascent biofilm structures (i.e., early bacterial aggregates)
(Fig. 2B). We then used immunogold transmission electron mi-
croscopy (TEM) to better localize Ply within 8-h biofilm struc-
tures and found that Ply localized to the bacterial cell well (arrow,
Fig. 2C) and to the extracellular matrix (arrow, Fig. 2D). Alto-
gether, these results confirm the specific localization of Ply to cel-
lular aggregates and suggest a role as a matrix protein.
Early biofilm assembly on polystyrene is impaired in a Ply-
deficient knockout. To examine whether Ply is essential for as-
sembly of pneumococcal biofilms, we constructed a Ply-deficient
knockout in D39 (see Fig. S1 in the supplemental material) and
examined the biofilm formation of this mutant as well as a TIGR4
derivative provided by Andrew Camilli (Table 1). While the
planktonic growth of the Ply-deficientmutants did not differ from
that of the corresponding wild-type strains (see Fig. S3 in the sup-
plemental material), the ability of the ply derivatives to form
biofilms was drastically impaired. Fluorescence microscopy of
GFP-expressing derivatives of D39, D39ply, AC2394 (TIGR4),
and AC4037 (TIGR4ply) demonstrated that biofilm formation
ability of the ply mutants was inferior to that of the wild-type
A B 
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FIG 2 Location of pneumolysin in pneumococcal biofilms. (A) Confocal
microscopy images of D39 (antipneumococcal antibody, green) and Ply (anti-
Ply antibody, red) indicate that pneumococcal cells and pneumolysin colocal-
ized in D39 biofilms at 24 h. (B) An image of differential interference contrast
(Nomarski) with a fluorescent anti-Ply overlay of 4-h wild-type D39 biofilms
revealed that pneumolysin localized to the earliest cellular aggregates in bio-
films grown on polystyrene. (C) Transmission electron microscopy of an 8-h
biofilm grown on A549 cells and treated with anti-Ply primary antibody and a
gold-conjugated secondary antibody reveals that Ply is located on the bacterial
surface (arrow) and in the extracellular matrix. (D) Another TEM image dem-
onstrates Ply located throughout the extracellular matrix (arrow) between
pneumococcal biofilm cells.
TABLE 1 Strains and plasmids used in this study
Strain or plasmid Description Reference or source
S. pneumoniae strains
D39 Avery strain, clinical isolate, capsular serotype 2 46
SPJV01 D39/pMV158GFP, Tetr 7
SPJV05 D39luxS Eryr 7
SPJV08 D39luxS/pMV158GFP Eryr Tetr 7
SPJV10 D39comC Eryr 27
SPJV14 D39ply Eryr This study
SPJV15 D39ply/pMV158GFP Eryr Tetr This study
Pn Reconstituted ply mutant 13
Ply306 D39 with ST 306 ply allele This study
AC2394 Acapsular TIGR4, invasive clinical isolate 47
AC2394gfp AC2394/pMV158GFP Tetr This study
AC4037 AC2394ply Spcr 47
AC4037gfp AC2394ply/pMV158GFP Spcr Tetr This study
CDC_881 Serotype 1 strain, ST306 L. McGee, CDC
CDC_1403 Serotype 1 strain, ST306 L. McGee, CDC
CDC_4829 Serotype 1 strain, ST306 L. McGee, CDC
Plasmid
pMV158GFP S. pneumoniaemobilizable plasmid encoding GFP;
confers resistance to tetracycline
48
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strains at 4 and 8 h (Fig. 3A). When absolute biofilm biomass was
examined using a fluorescein isothiocyanate (FITC)-conjugated
antipneumococcal antibody, we found that D39ply produced
significantly less biomass than the wild type (WT) at 6, 8, 10, and
12 h (P 0.05; Fig. 3B). While a comC knockout mutant formed
wild-type levels of biofilm biomass on abiotic surfaces, the luxS
and ply knockout mutants formed significantly less biofilm bio-
mass than the wild type (P 0.01) (Fig. 3C). Similar results were
obtained when biofilm assays were conducted using polystyrene
substrates and Dulbecco’s modified Eagle medium (DMEM)
(data not shown). As a control, we examined the previously char-
acterized complemented ply mutant Pn (13) and found that its
ability to form biofilms did not differ significantly from that of the
wild type (Fig. 3C).
To ascertain whether Ply released into the medium could be
sufficient to restore biofilm formation capability to cells lacking
endogenous Ply, we conducted experiments using Transwell per-
meable supports to separate strains of
bacteria while allowing the free flow of
nutrients and proteins. We grew three
combinations of strains in wells with
Transwell supports (given in the format
top/bottom),WT/WT,WT/plymutant,
and ply mutant/ply mutant. These
wells were incubated at 37°C for 10 h, and
biofilms on the bottom of the wells were
quantified using GFP fluorescence. We
found that the ply strain with wild-type
D39 above the Transwell barrier grew no
more biofilms than the ply strain with
ply organisms above the Transwell bar-
rier (Fig. 3C).
The pneumolysin deficient mutant
forms comparable biofilm biomass by
24 h, and cellular autolysis is delayed.
Quantification of biofilms formed at 18
and 24 h using a fluorescently conjugated
antipneumococcal antibody revealed that
comparable biofilm biomass was found
in wild-type and ply strains (Fig. 4A).
However, when biofilms were resus-
pended in phosphate-buffered saline
(PBS) and plated on blood agar plates
(BAPs), we found that more CFUs were
recoverable from the wild-type strain at
8 h and 18 h postinoculation, but at 24 h
postinoculation, there were no CFUs re-
coverable from wild-type D39 biofilms,
while D39ply and D39luxS biofilms
still yielded ~1  107 CFU/ml (Fig. 4B).
Fluorescence microscopy of GFP-
expressing D39 and D39ply at 24 h re-
vealed that the ply strain was more
metabolically active (as evidenced by
expression of GFP) than the wild-type
strain (Fig. 4C). Electronmicroscopy im-
ages directly illustrated pneumococcal
autolysis; while wild-type D39 cells in 8-h
biofilms contained electron-dense mate-
rial, wild-type D39 cells in 24-h biofilms
have disrupted cellular membranes and exhibit an absence of
electron-dense material (Fig. 4D). TEM of the ply knockout
mutant demonstrated healthy electron-dense cells at both 8 h and
24 h and also showed more surface-associated polysaccharide
than in the wild type at 8 h (Fig. 4D).
Ply-deficient D39 forms less biofilm than the wild type on
human cell line substrates. To verify that pneumolysin is neces-
sary for early biofilm formation under more physiologically rele-
vant conditions, we examined biofilm formation and ply expres-
sion in biofilms grown on human cell substrates under static and
continuous-flow conditions. When biofilm formation was as-
sessed using an A549 human lung cell substrate in static growth
conditions, we observed that wild-type D39 formed confluent
biofilms (Fig. 5A), while D39ply formed very little biofilm
(Fig. 5B). Quantitatively, the biofilm biomass of D39plywas sig-
nificantly less than that of the wild type 6 h (P 0.05) and 8 h (P
 0.01) postinoculation (Fig. 5C). In addition, when the strains
FIG 3 Ply knockout mutants form inferior biofilms on polystyrene at early time points. (A) GFP-
expressing D39, D39ply, AC2394 (TIGR4), and AC4037 (TIGR4ply) were incubated on glass slides
for 4 or 8 h, and biofilms were imaged with fluorescence microscopy. (B) Wild-type D39 and D39ply
biofilm biomasses on polystyrene plates at 6, 8, 10, and 12 h were quantified using a polyclonal FITC-
conjugated anti-pneumococcal antibody. Asterisks indicate P values of0.05. (C) Biofilm biomass of
D39comC, D39luxS, D39ply, and the complemented strain Pn (13) after 8 h of incubation. In
addition, biofilm biomass formed on the bottomof the well of Transwell experiments with the wild type
above and below, the wild type above and the plymutant below, and the plymutant above and below the
barrier, after 10 h of incubation. Values from both the 8-h single-well experiments and 10-h Transwell
experiments are expressed as percentages of the biofilm biomass of wild-type D39 at the respective time
points. Error bars indicate standard errors of the means, and asterisks indicate P values of0.01.
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were grown on top of Detroit 562 pharyngeal cells for 8 h, we
found that D39ply and D39luxS formed significantly less bio-
film biomass than the wild type (P 0.01) (Fig. 5D).
To better simulate in vivo conditions of pneumococcal biofilm
growth, we grew D39 biofilms on an A549 substrate in a continu-
ous flow bioreactor previously described (27). Confocal micros-
copy studies demonstrated that Ply coated the bacterial cell wall,
with the top section showing pneumococcal chains surrounded by
Ply (Fig. 6A) and a middle section showing abundant localization
of Ply within aggregated bacteria (Fig. 6B). In relation to the log-
phase planktonic inoculum, ply expression was upregulated ~6-
fold in cells grown on immobilized A549 under static conditions
for 8 h, ~2-fold in biofilms grown for 8 h in a bioreactor, and
~6-fold in biofilms grown for 24 h in a bioreactor (Fig. 6C).
Pneumococcal hemolytic activity is not essential for biofilm
formation. To examine whether the biofilm formation function
of pneumolysin was related to its hemolytic function, we exam-
ined the biofilm formation capability of serotype 1 strains belong-
ing to sequence type (ST) 306 that produce a variant of pneumo-
lysinwithminimal hemolytic activity (28). AlthoughWestern blot
analysis confirmed expression of Ply in the serotype 1 strains (see
Fig. S4 in the supplemental material), hemolytic activity assays
demonstrated the absence of hemolytic activity in D39ply and
the serotype 1 isolates CDC_881, CDC_1403, and CDC_4829
(Fig. 7A). However, these three serotype 1 strains displayed no
statistically significant difference in biofilm biomass at 8 h com-
pared to wild-type D39 (Fig. 7B). Biofilm formation capacity is
known to vary markedly between pneumococcal strains. Thus, to
ensure that the different genetic background of the serotype 1
strains did not affect the experiment, we constructed Ply306, a
D39 derivative expressing the nonhemolytic ply allele from ST
306, using methods described previously (29). We found that the
biofilm biomass formed by the Ply306 D39 strain did not differ
significantly from that of wild-typeD39 (Fig. 7B). Taken together,
these results suggest that Ply’s role in early biofilm formation is
independent of hemolytic activity.
As pneumococcal biofilms are present in the nasopharynxwith
no apparent epithelial damage, the incorporation of Ply into the
biofilm matrix may interfere with its hemolytic and cytotoxic ac-
tivity. We therefore examined the hemolytic activity of wild-type
D39 harvested from planktonic cultures in comparison to wild-
type D39 harvested from biofilms. While D39 harvested from
planktonic cultures maintained constant hemolytic activity over
time (Fig. 7C and D), the hemolytic activity of D39 in biofilms
FIG 4 Ply-deficient D39 biofilm formation is comparable to that of the wild type by 24 h, but cellular autolysis is delayed. (A) Biofilm biomasses of D39 and
D39ply grown on polystyrene for 12, 18, and 24 h, quantified using a FITC-conjugated antipneumococcal antibody. (B) Biofilms formed by D39, D39luxS,
and D39ply on polystyrene after 8, 16, or 24 h of incubation were resuspended in 1ml of PBS and plated on BAP to estimate CFU. The limit of detection of this
assay was 10 CFU/ml. (C) Fluorescence microscopy of GFP-expressing D39 and D39ply confirms that the number of enzymatically active cells is greater in
D39ply biofilms than in wild-type biofilms following 24 h of static incubation. (D) Transmission electron microscopy of wild-type D39 and the plymutant
grown on A549 cells demonstrates healthy D39 at 8 h and autolyzed cells at 24 h and healthy ply cells at both 8 and 24 h. Error bars indicate standard errors of
the means.
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decreased from 128 hemolytic units (HU)/mg at 6 h postinocula-
tion (Fig. 7C) to 64 HU/mg 8 h postinoculation (data not shown)
and further to 32 HU/mg at 10 h postinoculation (Fig. 7D). This
difference suggests that incorporation of pneumococcal cells into
biofilms is correlated with a decrease in hemolytic activity.
DISCUSSION
This study is the first to demonstrate that pneumolysin is essential
for the production of early pneumococcal biofilms. Not only was
Ply expressed in pneumococcal biofilms produced under static
and continuous-flow conditions on abiotic and human cell sub-
strates, but Ply knockout mutants produced significantly less bio-
film biomass than the wild type at early time points. Early aggre-
gates of pneumococci were the first to express pneumolysin, and
expression peaked with maximal biofilm formation at approxi-
mately 8 to 10 h postinoculation. Incorporation of cells into bio-
films led to a decrease in hemolytic activity, but the hemolytic
function of Ply appears to be separate from its role in biofilm
formation. In total, we have demonstrated that pneumolysin has a
previously unrecognized role, key in the
early stages of the biofilm formation pro-
cess.
Previous studies have alluded to a con-
nection between pneumolysin and bio-
film formation. Most evidence has been
circumstantial, demonstrating that bio-
film formation results in changes in ply
expression. In 2006, Oggioni et al. re-
ported extensive regulatory differences
between planktonic and sessile phases,
including the finding that in comparison
to mid-exponential-phase liquid cul-
tures, pneumococcal cells on agar and in
biofilms expressed 100-fold and 5-fold
less ply, respectively (30). Lizcano et al.
concluded that pneumolysin was not im-
portant in biofilm formation in TIGR4;
however their study only examined bio-
film biomass by measuring crystal violet
staining at 18 h postinoculation (31). Our
results indicate that after 18 h of growth,
cells in wild-type biofilms may have al-
ready begun to undergo autolysis, while
the Ply knockout mutant continues to
form more biofilm (7, 32). By examining
biofilm formation of wild-type strains
and isogenic mutants using various
growth conditions, multiple substrates,
and a variety of time points, we have
shown that there is an important role for
pneumolysin in the early stages of pneu-
mococcal biofilm development.
Confocal and electron microscopy lo-
calized pneumolysin to the pneumococ-
cal cell surface and extracellular matrix,
suggesting a linking role for this protein
during the aggregation phase of biofilm
formation. While altered degradation of
GFPmay be responsible for the difference
in autolysis witnessed by fluorescence,
our CFUmeasurements and TEM results clearly demonstrate that
the ply knockout mutant has delayed autolysis. This may be a
function of metabolic changes, perhaps resulting from altered
proximity to other bacterial cells. Previous studies have indicated
that presence of a capsule impairs pneumococcal biofilm forma-
tion (33, 34) and that genes in the capsule operon are down-
regulated during biofilm formation (35). The polysaccharide halo
surrounding the ply knockout cells imaged by TEM is consistent
with altered capsular regulation, but further studies are needed to
understand the role of capsular expression in pneumococcal bio-
film formation.
Pneumolysin has been recognized as a virulence determinant
for decades (36), and animal and human studies have indicated
that the hemolytic activity of pneumolysin is largely responsible
for pneumococcal virulence (37). However, the amount of hemo-
lytic activity necessary for virulence is reportedly just 0.1% of the
wild-type levels (13). Nevertheless, it was surprising when
Kirkham et al. reported the isolation of nonhemolytic serotype 1
strains from invasive pneumococcal disease (28). This result led
FIG 5 Ply-deficient D39 forms inferior biofilms when grown in static conditions on human lung cells.
Wild-type D39 (A) and D39ply (B) biofilms were grown under static conditions for 8 h on A549
human lung cell substrates. GFP-expressing bacteria are green, eukaryotic nuclei are blue, and eukary-
oticmembranes are red. (C)Wild-typeD39, D39luxS, andD39plywere grown on human lung A549
cells under static conditions for 2, 4, 6, and 8 h, and biofilm biomass was quantified using GFP fluores-
cence. The amount of biofilm biomass is shown as a percentage of that formed by wild-type D39 at 8 h.
At 6 and 8 h postinoculation, wild-type D39 formed significantly more biofilm biomass than D39luxS
or D39ply (P 0.05). (D) D39luxS and D39ply form significantly less biofilm than wild-type D39
when grown on Detroit 562 human pharyngeal cells for 8 h under static conditions. Error bars indicate
standard errors of the means, and asterisks indicate P values of0.01.
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those authors to speculate that an immune activation function of
pneumolysin may contribute to virulence; this hypothesis is sup-
ported by the findings of Malley et al. showing that pneumolysin
induces a substantial immune response bymacrophages (17). The
results of our study raise the possibility that pneumolysin’s con-
tribution to pneumococcal virulence may be partially attributed
to its role in biofilm formation. At the same time, our finding that
pneumococcal hemolytic activity of cells decreases as biofilms are
formed may indicate that incorporation of cells into the biofilm
matrixmaymask the hemolytic epitope and prevent pneumolysin
from provoking a clearing immune response during carriage.
Recently we demonstrated that LuxS/AI-2 regulates early
pneumococcal biofilm formation (7, 8) and observed that a luxS
null mutant expressed lower mRNA levels of the pneumolysin
gene than the wild type. In a follow-up study, we demonstrated
that both the LuxS/AI-2 and Com quorum-sensing systems regu-
late biofilm production in a bioreactor with living cultures of hu-
man respiratory cells (27). Our finding that pneumolysin is down-
regulated in a luxS knockout mutant but not in a comC knockout
mutant appears to indicate that pneumolysin is predominantly
under the regulatory control of the LuxS/AI-2 system. From these
results we can hypothesize that LuxS-regulated pneumolysin plays
a critical role in early aggregation, while other factors regulated by
Com contribute to biofilm maturation. The components of bio-
film assembly and maturation, and the regulation of those com-
ponents, are a subject in need of further study.
Our results suggest that pneumolysin directly contributes to
early aggregation of pneumococcal cells into early biofilms. Given
that pneumolysin is an important candidate antigen for the devel-
opment of a serotype-independent vaccine (19–21, 38, 39), our
FIG 6 Pneumolysin is expressed in biofilms produced on human lung cells in
a continuous-flow bioreactor. (A) The optical top section from a bioreactor
with wild-type D39 biofilm cells on an A549 human cell substrate after 8 h of
growth. Cells and biofilms were fixed, nuclei were fluorescently stained with
TO-PRO-3 (blue), andPlywas stainedwith an anti-Ply antibody (red). Arrows
indicate GFP-expressing pneumococci (green) surrounded by Ply, enlarged in
the inset. (B) The middle section from the same 8-h bioreactor demonstrates
abundant Ply expressedwithin pneumococcal biofilm aggregates grown in this
model system. (C) Reverse transcription and qPCR of RNA extracted from
biofilms grown on immobilized cells in static culture for 8 h or in a
continuous-flow bioreactor for 8 or 24 h demonstrate that ply is upregulated
relative to the inoculumwhen the bacteria are grown on A549 cells. Error bars
indicate standard errors of the means.
FIG 7 Hemolytic activity and biofilm phenotypes. (A) D39, D39ply, and three serotype 1 isolates were examined for hemolytic activity. Wild-type D39
possessed hemolytic activity, while all other strains examined had almost none. (B)When biofilm formation capability was assessed, CDC_881, CDC_1403, CDC
4829, and Ply306 exhibited biofilm biomasses similar to that of wild-type D39. (C) Wild-type D39 cells harvested from planktonic and biofilm cultures assayed
for hemolytic activity did not differ in hemolytic activity at 6 h postinoculation. (D) Planktonic and biofilm cultures of D39 harvested 10 h postinoculation
demonstrate a marked difference in hemolytic activity. Error bars indicate standard deviations, and the asterisk indicates a P value of0.01.
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characterization of pneumolysin’s role in biofilm formation has
important implications. Carriage of the pneumococcus is a neces-
sary precursor to pneumococcal diseases (40) and if Ply is rou-
tinely expressed in nasopharyngeal biofilms, its potential as a vac-
cine antigen is more easily understood. These results highlight the
urgent need for further exploration of pneumolysin and the im-
mune response against it, using both in vivo and in vitromodels of
biofilm formation.
MATERIALS AND METHODS
Strains and bacterial culture methods. The S. pneumoniae reference and
derivative strains used in this study are listed in Table 1. Strains were
cultured onTrypticase soy agar BAPs or in Todd-Hewitt broth containing
0.5% (wt/vol) yeast extract (THY). When biofilm formation was visual-
ized or quantified using GFP-expressing strains, 2% (wt/vol) maltose was
added to the culturemedium. Inocula for all biofilm assays were prepared
using growth on an overnight BAP to prepare a cell suspension in THY
broth at an optical density at 600 nm (OD600) of 0.05. This suspensionwas
incubated at 37°C in a 5% CO2 atmosphere until the culture reached an
OD600 of 0.2 to 0.3 (early log phase); glycerol was added to a final concen-
tration of 10% (vol/vol), and the suspension was stored at 80°C until
used.
Growth of biofilms on abiotic and biotic surfaces. For experiments
conducted on abiotic surfaces, 24-well Costar polystyrene plates (Corn-
ing, Tewksbury, MA) were used for quantification experiments, and
8-well Lab-Tek II glass chamber slides (Thermo, Fisher Scientific, Rock-
ford, IL) were used for visualization experiments.Wells or chambers were
filled with THY medium, inoculated 1:10 with inocula prepared as de-
scribed above, and incubated at 37°C for various lengths of time. When
indicated, experiments used Transwell permeable supports (Corning,
Tewksbury, MA) with 0.4-m pores to separate strains of bacteria within
wells of 24-well plates while allowing the free flow of nutrients and se-
creted proteins.
To simulate the environment in the human respiratory tract, a human
cell line substrate was employed, in both static and continuous-flow cul-
tures, as recently described (27). Briefly, human-derived lung A549 cells
(ATCCCCL-185) or human-derived pharyngeal Detroit 562 cells (ATCC
CCL-198) were grown on polystyrene plates or Snapwell filters (Corning,
Tewksbury, MA) until confluent (4 to 5 days). For static experiments,
human cells were fixed with 2% paraformaldehyde (Sigma) for 15 min.
Following several washes with PBS, immobilized human cells were inoc-
ulated with prepared bacterial inocula (~7 105 CFU/ml) and incubated
in DMEM at 37°C for various times. For continuous-flow experiments,
confluent cells on Snapwell filters were inoculated as detailed above and
immediately placed in a sterile vertical diffusion chamber (27). Both ba-
solateral and apical sides (inner chamber) were perfused with sterile
DMEM with no antibiotics using a Master Flex L/S precision pump sys-
tem (Cole-Parmer, Vernon, IL) at a low flow rate (0.20 ml/min). Biore-
actor chambers containing S. pneumoniae and lung cells were incubated at
37°C in a sterile environment. At the end of the incubation period, inserts
containing biofilms were removed, and biomass was analyzed qualita-
tively and quantitatively.
Visualizing pneumococcal biofilms. When GFP-expressing strains
were used, biofilms on microtiter plates were washed with PBS and visu-
alized by fluorescence microscopy, or biofilms produced on 8-chamber
slides were washed with PBS, fixed with 2% paraformaldehyde, and
mounted with Vectashield (Vector Laboratories, Burlingame, CA), and
fluorescence was visualized with an inverted Evos FL microscope (Ad-
vancedMicroscopy Group, Carlsbad, CA) or confocal microscopy.When
non-GFP-expressing strains were used, biofilms were fixed with 2% para-
formaldehyde (Sigma-Aldrich, St. Louis, MO) for 15 min, washed with
PBS, blocked with 2% bovine serum albumin, and stained for 1 h at room
temperature with a polyclonal anti-S. pneumoniae antibody (~40 g/ml)
coupled to fluorescein isothiocyanate (FITC; ViroStat, Portland, ME).
Where indicated, Ply was detected using 2.0 g/ml unconjugated mouse
monoclonal anti-Ply antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), followed by an Alexa Fluor 568 goat anti-mouse IgG secondary an-
tibody (Molecular Probes, Invitrogen, Carlsbad, CA). For preparations
from the human cell bioreactor system, sialic acid residues present on the
plasma membranes were stained with 5 g/ml wheat germ agglutinin
conjugated with Alexa Fluor 555 (Molecular Probes, Invitrogen, Carls-
bad, CA) for 30 min (41), and nucleic acids were stained with TO-PRO-3
(1 M), a carbocyanine monomer nucleic acid stain (Molecular Probes,
Invitrogen, Carlsbad, CA) for 15 min. Finally, preparations were washed
three times with PBS, mounted with Vectashield mounting medium
(Vector Laboratories, Burlingame, CA), and analyzed with a Zeiss
LSM510 confocal microscope. Confocal images were analyzed with an
LSM image browser, version 4.0.2.121.
For immunogold localization of Ply, 8-h biofilms grown on top of
A549 lung cells were fixed with either 2 or 4% paraformaldehyde (PFA) in
0.1Mphosphate buffer (PB) overnight at 4°C. Cells were thenwashed and
treated with 0.05% Triton X-100 for 10 min before blocking with PBS
containing 5% bovine serum albumin (BSA) and 0.1% cold-water-fish
gelatin. Mouse anti-Ply primary antibody was diluted to 8 g/ml in PBS
containing 0.1% acetylated BSA for overnight incubation. After washes,
cells were incubated overnight with ultrasmall-colloidal-gold-conjugated
goat anti-mouse IgG secondary antibody (Aurion, Wageningen, the
Netherlands), followed by washes and postfixation in 2.5% buffered glu-
taraldehyde. Silver enhancement of ultrasmall gold particles was carried
out using R-gent SE-EM silver enhancement kit (Aurion, Wageningen,
the Netherlands) following the manufacturer’s instruction. Cells were
then fixed with 0.5% osmium tetroxide, dehydrated, and embedded in
Eponate 12 resin. Ultrathin sections were counterstained with 5% uranyl
acetate and 2% lead citrate and examined on a JEOL JEM-1400 transmis-
sion electron microscope (JEOL Ltd., Japan) equipped with a Gatan Ul-
traScanUS1000 charge-coupled device (CCD) camera (Gatan, Inc., Pleas-
anton, CA).
Quantification of biofilm biomass. Biofilm biomass was quantified
by fluorescence methods as previously described (7, 27) or by serial dilu-
tion followed by plating to obtain cell counts (CFU/ml). For GFP-
expressing strains and biofilms stained with a FITC-conjugated antibody,
arbitrary relative fluorescence units (RFU) were obtained using a Victor
X3 multilabel plate reader (PerkinElmer, Waltham, MA). The number of
arbitrary fluorescence units of wild-type D39 was set to a biofilm biomass
of 100% and used to calculate the biofilm biomass percentages of all of the
other S. pneumoniae strains tested and those at different time points.
Results of repeated experiments were plotted using GraphPad Prism or
SigmaPlot and examined for statistical significance with two-tailed t tests
for normal data and Mann-Whitney U tests for nonparametric data.
Western blot assays. To compare the expression of Ply in biofilm and
planktonic cells, bacterial cells were treated with the B-PER bacterial pro-
tein extraction reagent (Thermo, Fisher Scientific, Rockford, IL) accord-
ing to the manufacturer’s protocol and quantified using the Bradford
protein assay (42). A 5-g portion of extracted protein was loaded into
each well on a 12% polyacrylamide gel, subjected to SDS-PAGE, and
transferred onto a nitrocellulose membrane. Those membranes were
blocked with PBS with 0.05% (vol/vol) Tween 20 and 5% (wt/vol) nonfat
dry milk for 1 h and then probed with a 1:200 dilution (final concentra-
tion, 0.5 g/ml) of mouse anti-Ply monoclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) (43). Bound antibody was detected with
a horseradish peroxidase-conjugated secondary anti-mouse antibody di-
luted 1:10,000 and addition of Pierce ECL Western blotting substrate
(Thermo, Fisher Scientific, Rockford, IL).
Construction of D39 derivatives with ply knocked out or modified.
A ply knockout mutant was generated by PCR ligation mutagenesis as
previously described (44) (see Fig. S1 in the supplemental material).
Briefly, the construct was generated by PCR amplification of a 5= segment
of the ply gene with primers HPL1 and HPL2 and a 3= segment with
primers HPL5 and HPL6. Primers HPL3 and HPL4 were used to amplify
the ermB gene, encoding erythromycin resistance, and to add XbaI and
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XhoI restriction sites to the ends (7). The 5= and 3= segments were ligated
to the gene encoding erythromycin resistance using T4 DNA ligase, and
the cassette was generated by amplificationwith primersHPL1 andHPL6.
A 100-ng portion of the cassette was then transformed into competent
D39 cells, and the SPJV14 (D39ply) recombinants were selected for on
BAP containing 0.5 g/ml of erythromycin. Knockouts were confirmed
by PCR (see Fig. S1 in the supplemental material), sequencing (data not
shown), and Western blotting (see Fig. S4 in the supplemental material).
A derivative of D39 expressing the nonhemolytic ply allele from an
S. pneumoniae type 1 ST 306 strain was constructed by allelic replacement
using an analogous protocol and the primers employed for construction
of a derivative expressing the ply4496 allele, which has significantly less
hemolytic activity (29).
Hemolytic activity assay. Pneumococcal cells were prepared for assay
by growth in THY to mid-log phase (OD600, 0.3 to 0.4) and 10 concen-
tration before resuspension in PBS. Bacterial cells were lysed with a 10-
min incubation at 37°C in 0.1% sodium deoxycholate solution, and then
protein was quantified using the Bradford assay. Sheep red blood cells
(RBCs) were washed three times using PBS. RBCs (2 ml) were added to
32 ml PBS and 50 l -mercaptoethanol to make a 3% RBC preparation.
Serial 2-fold dilutions of 17 g of each protein preparation were made in
PBS in microtiter plates before addition of 50 l of the 3% RBC prepara-
tion and incubation for 30 min at 37°C. Unlysed RBCs were pelleted by
centrifugation, and supernatant was transferred to a new microtiter plate
for measurement at A540. A540 values were plotted against the dilution
factor. Hemolytic units are defined as the lysate dilution factor when he-
molysis is 50% of that of wild-type D39.
Gene expression studies. Suspensions of biofilm cells or planktonic
cells were combined with an equal volume of RNA Protect (Qiagen Inc.,
Valencia, CA). Total RNA was extracted with an RNeasy minikit (Qiagen
Inc., Valencia, CA) and treated with 2 U of DNase I (Promega, Madison,
WI) as previously described (7). The integrity of RNA preparations and
the concentrations of samples were assessed using a NanoDrop ND-1000
spectrophotometer (Thermo, Fisher Scientific, Wilmington, DE). Total
RNA was reverse transcribed into cDNA using an iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA), using the manufacturer’s instructions.
Quantitative PCR (qPCR) was performed with generated cDNA using
SYBR green (Bio-Rad, Hercules, CA) and a CFX96 real-time PCR detec-
tion system (Bio-Rad, Hercules, CA). qPCRs were performed in duplicate
with 30 ng of total RNA, a 250 nM concentration of the primers JVS59L
and JVS60R to quantify ply transcripts (Table 2), and the following con-
ditions: 1 cycle of 95°C for 3 min, 40 cycles of 95°C for 30 s and 55°C for
30 s, and 1 cycle of 72°C for 1min.Melting curves were acquired on SYBR
green channel from 65°C to 95°C with 0.5°C increments. Relative quan-
tities of mRNA expression were normalized to the constitutive expression
of the housekeeping 16S rRNA gene (7) calculated by the comparative
2(CT) method (45). Error bars in the figures represent the standard
errors of the means calculated using data from three independent exper-
iments.
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